The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NMRD | +9,900% | -100% | -88.1% | -100% |
| S&P | +14.77% | +87.2% | +13.35% | +236% |
Nemaura Medical, Inc. operates as a holding company. The firm engages in the provision of medical device research. It manufactures and commercializes glucose monitoring system, named sugarBEAT. The sugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in New York, NY.
The clinical-stage upstart is raising money via a stock offering that dilutes existing investors.
The clinical-stage upstart is making progress in advancing a new type of glucose monitor to market.
| Q4 2023 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$80.43K | 0.0% |
| Market Cap | $6.33M | 0.0% |
| Net Income | -$2,161.48K | 0.0% |
| EBITDA | -$1,460.82K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2023 | YOY Change | |
|---|---|---|
| Net Cash | $137.42K | 0.0% |
| Inventory | 3.7 | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $19.64M | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Return On Assets | -117.49% | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,490.00K | 0.0% |
| Operating Free Cash Flow | -$1,479.57K | 0.0% |
| Metric | Q4 2023 | YoY Change |
|---|---|---|
| Price to Book | -0.40 | - |
| Price to Tangible Book Value | -0.39 | - |
| Enterprise Value to EBITDA | -17.68 | - |
| Total Debt | $19.64M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
